Similarly, targeting the POU2AF2-SWI/SNF axis, a key driver of SCLC-P, has emerged as a potential therapeutic strategy, with EZH2 inhibitors demonstrating efficacy in disrupting this pathway [165, 166]. Here, EZH2 is linked to small cell lung carcinoma.